InvestmentPitch Media Video Discusses LOVE Pharma's Launch of its First Two Products, BLOOM and AURALIEF - Video Available on Investmentpitch.com

Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) an international sexual health, wellness, and psychedelics company, launches its first two products, BLOOM™ and AURALIEF™.

Zachary Stadnyk, CEO, stated: "It is with great excitement that we are able to announce the launch of our first two fully-branded products, Bloom and Auralief. We believe these two products within our strong portfolio of intellectual property can quickly command significant market share in the shortest period. We look forward to updating our investors as we progress through the rollout of these first two products and subsequently, the company's therapeutic and wellness products in a strategic, staggered approach."

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Love Pharma" in the search box.

BLOOM™ is a topical female arousal gel providing increased lubrication and sensitivity that arouses the user, thereby addressing issues of female sexual disfunction. It is also designed to be sold as an over-the counter product without CBD or THC.

AURALIEF™, an oral muco-adhesive sublingual strip, infused with THC and/or CBD, enhances the bioavailability of THC and CBD, thereby increasing the impact of its health elements. By delivering THC and CBD into the system more quickly and efficiently than conventional methods it expedites and enhances the beneficial effects of THC and CBD within the body.

Joshua Maurice, COO, added: "Bringing any product to market is exciting, and with BLOOM™-our exclusive formula proven to enhance women's arousal we're excited for our new branded launch."

Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness.

The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

The shares which began trading on the CSE on September 30, are trading at $0.065. For more information, please visit the company's website www.love-pharma.com, contact Zach Stadnyk, President and CEO, at 604-343-2977 or toll free at 1-833-604-LOVE (5683) or by email at investors@love-pharma.com.

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.


InvestmentPitch Media
Barry Morgan, CFO

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101266

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Principal Technologies (TSXV:PTEC)

Principal Technologies Announces New Stock Option Plan

Principal Technologies Inc. (the "Company") (TSXV: PTEC), is pleased to announce that the Board of Directors of the Company (the "Board") has approved the adoption of a new 20% fixed stock option plan (the "New Option Plan").

On July 11, 2023, the Board adopted a 10% fixed stock option plan (the "Considered Plan") (see press release date July 11, 2023). The Considered Plan was subject to approval by the TSX Venture Exchange (the "Exchange") and would be in addition to the Company's 10% rolling stock option plan (the "Option Plan") that was last approved by shareholders at their annual general and special meeting held on November 30, 2022. Upon review and consultation with the Exchange, the Board has subsequently adopted the New Option Plan.

Keep reading...Show less
"Wrap-around Care" Model Helps Address Gaps in Mental Healthcare

"Wrap-around Care" Model Helps Address Gaps in Mental Healthcare

With over 1.3 million Canadians currently struggling with trauma and post-traumatic stress disorder (PTSD), Pure Life Healthcare Management is working to offer a wrap-around care model for better healing, according to CEO Doug Page.

The model allows individuals to walk in and have a single health provider deliver a wide spectrum of support for healing.

“What we’re trying to do is build out both from a telehealth perspective with physical locations where you’re able to walk in and get 20 different services … Some clients might only need two or three services. Some clients are going to be accessing that dozen-plus different services, depending on what their background is,” Page said.

Keep reading...Show less
pills spilling out of a pill bottle on a yellow background

Pharma Stocks: 5 Biggest Companies

The biggest pharmaceutical companies in the world are responsible for developing and manufacturing the vast majority of prescription drugs, giving them a key role in the life science industry.

The pharma sector is responsible for the discovery, development and manufacturing of drugs and medicine. Companies are developing innovative treatments in areas like immuno-oncology and neurology, as well as novel options for rare diseases. 2023 in particular has seen a lot of buzz around diabetes and weight loss treatments.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, the need for the industry is great. Opportunities for investment are also sizeable, but what's the best place to start? Those who want exposure to the pharma market may want to begin by looking at the major players in the space.

Keep reading...Show less
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today that study results demonstrated an experimental model of pericarditis induces mesothelial to mesenchymal transition ("MMT") and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in CardiolRx™. An abstract summarizing these results was submitted by the Company's international research collaborators from the University of Virginia and Houston Methodist DeBakey Heart & Vascular Center to the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases ("MPD2023") held on November 15 and 16, 2023 in Belgrade, Serbia.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics

Cardiol Therapeutics

Keep reading...Show less

Jamieson Wellness Inc. Reports Strong Third Quarter 2023 Results

Consolidated revenue growth of 9.1%;
Jamieson Brands revenue grew 15.0% led by increased demand in the U.S. and China

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported its third quarter results for the period ended September 30, 2023. All amounts are expressed in Canadian dollars.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News